US Stock Market Movement: ResMed Drops Sharply on October 30th Due to Slightly Lower Guidance, Sudden Decline in Life Support, and Margin Compression

ResMed October 30 Sharp Decline Interpretation

Keywords: Slightly Lower Guidance, Life Support Plummets, Margin Decline

1. On October 29, the company issued fiscal year 2027 revenue guidance of $5.75 billion to $5.85 billion, below the institutional forecast of $5.814 billion; although both adjusted EPS and revenue for the quarter exceeded expectations, full-year revenue guidance was slightly lower.

2. On October 29, the financial report showed that due to the termination of Astral sales, life support device revenue in the Americas dropped by 94% year-on-year to less than $1 million, and in other regions around the world fell by 79% to $3 million; the company expects that exiting Astral will reduce fiscal 2027 revenue growth by about 130 basis points, approximately $75 million.

3. On October 29, the financial conference call disclosed a non-GAAP operating margin of 35.8%, down 30 basis points year-on-year; restructuring and transformation costs for the quarter totaled about $29 million, and a $42 million provision was recorded related to Astral; MatrixCare's divestiture caused residential care software revenue to drop 7%.

(Disclaimer: This content is generated by AI technology summarizing publicly available information and is for reference only. It does not constitute investment advice.)